Page 5 - Serum Institute Of India

SII informs Centre it will supply around 200 mn Covishield doses in Sep

SII has informed the Centre that it will be able to supply around 20 crore doses of COVID-19 vaccine Covishield in September itself to Government to India and private hospitals, official sources said

Serum Institute picks up 50% in glass vial maker Schott's Indian JV

Deal value not disclosed; former co-promoters Kaisha exits JV

India's Serum Institute takes 50% stake in drug vial maker Schott Kaisha

SII, the world's largest vaccine maker by production volume, has taken a 50% stake in Indian drug vial maker Schott Kaisha, the companies said in a statement on Tuesday.

Serum Institute buys 50% stake in pharma packaging firm Schott Kaisha

The joint venture is for pharmaceutical packaging

Serum chairman Cyrus Poonawalla against using cocktail of Covid vaccines

Serum Institute of India (SII) chairman Dr Cyrus Poonawalla on Friday said he was not in favour of administering two different coronavirus vaccines for better efficacy. Poonawalla, whose firm makes the Covishield vaccine, was speaking to reporters after receiving the Lokmanya Tilak National Award here. "I am against the mixing of two different vaccines. There is no need to mix two different vaccines," he said, when asked about a recent ICMR study that a cocktail of Covishield and Covaxin could generate better immunity. "If cocktail vaccines are administered and if the result is not good, then SII may say that another vaccine was not good, vice versa, the other company might say that since you mixed Serum's vaccine, it did not give desired results," Poonawalla said. The efficacy of this approach has not been proven in field trials involving thousands of participants, he added. A study by the Indian Council of Medical Research involving 98 people, 18 of whom had inadvertently ...

Covid-19 vaccine export ban 'very bad' move: SII chairman Cyrus Poonawalla

Cyrus Poonawalla, chairman of SII, on Friday termed the ban on Covid-19 vaccine exports imposed by the Union government a very bad move, saying it put his company,in a difficult situation

Bureaucratic red tape, licence raj came down under Modi govt: SII chairman

Chairman of vaccine maker Serum Institute of India (SII), Dr Cyrus Poonawalla, on Friday hailed the Modi government saying that red-tapism and licence raj have come down under its rule.

Covid-19 pandemic: Novavax shot may get nod in India even before US

SII and Novavax have now completed submission of all modules required by regulatory agencies in India, Indonesia and the Philippines for the initiation of review of the vaccine

Mixing Covaxin and Covishield safe, gives better immune response: ICMR

The study was conducted on 18 individuals who inadvertently received Covishield as first jab and Covaxin as second in UP at a gap of six weeks

Covishield-Covaxin combination works better than 2 doses of same jab: ICMR

Study also found that the combination was safe and adverse effects were found to be similar when compared to the same-dose regimen

Hopeful of launching Covovax for adults in October this year: Serum CEO

Poonawalla met Home Minister Amit Shah in Parliament and the meeting between the two lasted for 30 minutes.

Production of 1.35 bn vaccine doses between August, December a long haul

Covishield production to cross 120 mn doses a month, Covaxin 58 mn doses a month

Serum Institute may start Covid-19 vaccine trials on kids in August

SII will conduct trials on those aged between two to 17 years

Covid-19 pandemic: SII partners CII in push to vaccinate rural areas

SII will be working with the CII, which has set up vaccination camps in smaller towns and rural areas

Expert panel recommends trials on mixing Covaxin and Covishield

As per sources, the application of the interchangeability study protocol of Covishield and Covaxin was moved by Christian Medical College (CMC) in Vellore.

Govt recommends nod to SII for phase 2/3 trials of Covovax on children

An expert panel of India's Central Drug Authority recommended granting permission to Serum Institute of India for conducting phase 2/3 trials of Covid vaccine Covovax on children aged 2 to 17 years

Expert panel recommends nod to SII for phase 2/3 trials of Covovax for 2-17

The trials would cover 920 children, 460 each in the age-group of 12-17 and 2-11 across 10 sites.

Covishield at Delhi govt vaccine centres reserved for 2nd dose till Jul31

Delhi government issued an order to reserve Covishield shots only for beneficiaries whose second dose is due, across all its vaccination centres till July 31.

SII writes to Mandaviya proposing reforms in drug regulatory system

Serum Institute of India (SII) has written to Union Health Minister Mansukh Mandaviya suggesting reforms in the existing drug regulatory system

What is the controversy surrounding Serum Institute's Covishield and EMA?

The vaccine did not make it to the European regulator's approved list, although it has been approved by WHO and also the UK MHRA